Startup · $4m raised
Sydney, NSW
Every investor coverage indicates participated in a round Skin2Neuron raised.
| Investor | Rounds | Invested |
|---|---|---|
| SYNthesis BioVentures | Unnamed stage | - |
Companies Skin2Neuron acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Bill Manos | Founder | SmartCompany, Synthesis BioVentures |
| Professor Michael Valenzuela | Founder | SmartCompany, Synthesis BioVentures |
Stories naming Skin2Neuron. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Wholesale Investor's Steve Torso highlights Australian life sciences companies from the Emergence Preview Series, noting government grant funding, a Series A extension, venture co-investment, and a medtech company's ASX listing.
Also Wholesale Investor
Government-backed CUREator+ program awards non-dilutive funding to seven Australian companies developing dementia and cognitive decline therapeutics, devices and digital health tools.
Profile of scientist-entrepreneur Andrew Wilks covering the GSK sale of his cancer molecule, his SYNthesis BioVentures fund's family-office backers, and portfolio plays including Aculeus Therapeutics.
Manufacturing roundup: Nova Systems wins a Norwegian contract, R.M. Williams opens a women's boot line, International Graphite secures government grants, three biotechs win NSW Biosciences Fund awards, and Lazo Paper is fined.
Also @AuManufacturing
Weekly roundup of four raises: Guzman y Gomez banked $134.5 million at a $1.73 billion valuation, Honey Insurance sealed a $108 million Series A, Skin2Neuron gathered $4 million, and AVESS Energy took $1 million.
Also SmartCompany
Sydney biotech Skin2Neuron raised $4 million from SYNthesis BioVentures to develop a hair-follicle cell therapy for Alzheimer's, while the investor reached the first $20 million close of its $75 million bioscience fund.
Also SmartCompany